10 noviembre 2014
Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. Removing some of the guesswork in diagnosis and treatment may lead to more successful outcomes.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/e9OIFWnWhrQ/141110123457.htm
